Sharla-Louise Tover
Psychiatric/Mental Health · Reno, NVNPI 1992401400
Payments from drug & device makers
Across 117 payments — averaging $22.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Vanda Pharmaceuticals Inc.$336
- Tris Pharma Inc$252
- Neurocrine Biosciences, Inc.$122
- E.r. Squibb & Sons, L.L.C.$121
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$102
- plus $659 from 13 others
What the payments were for
- Food & beverage$2,677100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 45 | $1,085 |
| Vanda Pharmaceuticals Inc. | 17 | $336 |
| Tris Pharma Inc | 13 | $252 |
| Neurocrine Biosciences, Inc. | 5 | $122 |
| E.r. Squibb & Sons, L.L.C. | 5 | $121 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $102 |
| Idorsia Pharmaceuticals US Inc | 5 | $92 |
| Lundbeck LLC | 3 | $83 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $83 |
| Teva Pharmaceuticals USA, Inc. | 2 | $68 |
| Otsuka America Pharmaceutical, Inc. | 3 | $67 |
| Almatica Pharma LLC | 2 | $50 |
| Alkermes, Inc. | 2 | $49 |
| Ironshore Pharmaceuticals Inc. | 2 | $48 |
| Indivior Inc. | 2 | $39 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $28 |
| Corium, LLC | 1 | $22 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| Luye Pharma (USA) Ltd. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$342
How this compares
$2,677 in reported general payments places this provider in the 80th percentile of 362 psychiatric/mental health providers in Nevada.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 27 | $39,217 |
| Naltrexone Hcl | 14 | $1,447 |
| Quetiapine Fumarate | 42 | $799 |
| Olanzapine | 23 | $667 |
| Oxcarbazepine | 12 | $457 |
| Lamotrigine | 40 | $427 |
| Bupropion XlBupropion Hcl | 24 | $403 |
| Vilazodone Hcl | 11 | $380 |
| Fluoxetine Hcl | 23 | $377 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 12 | $367 |
| Escitalopram Oxalate | 39 | $312 |
| Trazodone Hcl | 45 | $308 |
| Gabapentin | 44 | $306 |
| Citalopram HbrCitalopram Hydrobromide | 13 | $302 |
| Buspirone Hcl | 23 | $294 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $1,085 | $39,21727 claims |
| Almatica Pharma LLCSertraline Hcl | $50 | $18621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 362 psychiatric/mental health providers in Nevada.
Other psychiatric/mental health in Reno
- Okechukwu OlisaReno$7K
- Kaiwen JiangReno$6K
- Alana RogneReno$6K
- Doris AnukamReno$5K
- Megan SeivertReno$4K
- Denis WilliamsReno$4K
- Nathanael MellumReno$3K
- Jacqueline WilliamsReno$3K
- Michelle GiddingsLas Vegas$131K
- Patrick ApiladoLas Vegas$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.